President Obama’s JAMA article provided facts and statistics that showed a significant decline in the number of uninsured individuals in the U.S. This provides evidence that the ACA is serving its purpose. What surprised me the most about the JAMA article was President Obama’s stance on the need for profit checking in relation to drug costs. Many medications that people with rare conditions need are new innovations, and extremely expensive. This is especially true when these new medications have met the FDA’s requirements for exclusivity, and cannot be produced in a generic form. In the article, President Obama supports the creation of legislation that would increase the transparency of manufacturing costs. I believe this legislation is necessary, and will ensure that Pharmaceutical companies are kept in check, so profit does not become greed.
Personally, I am quite worried about Trump’s promise to repeal the ACA if he is elected into office. Passing the ACA was a tedious and lengthy task, and if the ACA is repealed we will lose much of the progress we have made in health care reform as a country.
In regards to changes I would like to see in the future, I strongly believe we need a publicly funded/socialized healthcare system as a developed nation. I am certain this will not occur in the near future due to hyper partisanship, but I believe healthcare should be a basic human right, especially in a developed nation like ours.
Second, I would like to see a more reasonable balance between legislation that incentivizes innovation through increased profits, and legislation that keeps medical costs low for the protection of the consumer. “Big pharma” is slowly but surely becoming blatantly profit hungry even when this endangers the lives of others. This has happened many times in the past and continues to happen today.
The Turing CEO increased the price of a Daraprim, used to treat toxoplasmosis, from $13.50 a pill to $750 overnight at the end of last year.
The Mylan CEO has slowly raised the retail cost of two Epi-pens from $100 in 2007 to over $600 today. The kicker? All Mylan executives have pocketed multimillion dollar salary increases, and the estimated production cost of the 2 pen unit is about $8.
Stronger legislation is needed to keep these companies like these in line.